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Introduction
Merkel cell carcinoma (MCC) of the skin was formerly 
called trabecular carcinoma. It is an uncommon, highly 
malignant primary cutaneous neuroendocrine carcinoma. 
MCC occurs mostly in white elderly patients, usually with 
an equal incidence in men and women, although it may 
be slightly more common in females [1]. About 78% 
of patients are older than 59 years. Female and male 
patients are equally involved in the age group below 60 
years. After 60 years, MCCs are more often observed 
in female patients. The tumour is most often located 
in the head and neck region (50.8%) or the extremities 
(33.7%). The average size is 29 mm at presentation. 
Clinically, only a presumptive diagnosis of MCC can 
be established. The definitive diagnosis is made by 
histological, especially immunohistological, methods: 
detection of intermediate filaments and neuroendocrine 
markers [2]. The exact aetiology of MCC is not known, 
but it is postulated that it might be related to sunlight. 
Recent studies demonstrate chromosomal abnormalities 
in chromosomes 1, 11 and 13 [3].
The immunological aspect of the cancer is in-
teresting, because at least 10 cases of spontaneous 
remission, complete or partial have been reported in the 
literature [4, 5]. MCC occurs more frequently in immuno-
suppressed patients and there are occasional reports of 
cure with tumour necrosis factor [6] and interferon [7].
There are some controversies in the literature regar-
ding treatment; whether adjuvant treatments should be 
given and what is the best modality. The appropriate 
treatment in recurrent and metastatic disease becomes 
a dilemma due to its occurrence in the elderly who tend 
to tolerate aggressive treatment poorly. We reviewed 
cases of this interesting disease which were available in 
our two institutions and in the literature.
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We examine the impact of radiotherapy in the treatment of Merkel cell carcinoma (MCC) of the skin. Data at two Canadian 
institutions (Allan Blair Cancer Centre and London Regional Cancer Program) were collected and charts were retrieved 
from the registry of 1987 to 2005. A total of 79 patients with definite MCC were studied. All except three had a primary skin 
lesion. Six patients presented with nodal metastases and three patients with distant metastases. Fourteen patients were referred 
to the cancer centers at the time of recurrence: 2/14 with local recurrence, 8/14 with nodal recurrence, 2/14 with both local 
and nodal recurrence, and 2/14 with distant recurrence. The series consisted of 40 males and 39 females with a median age 
of 80 years (range 48-94). The median follow up was 21 months (range 0.5-150.4).
Twenty-two patients (group A) received radiotherapy at the time of presentation,21 being post-operative adjuvant treatment 
and one being primary treatment without surgery. The 5-year cause-specific survival rate (CSSR) was 42%. The 5-year rates 
equals the 10-year rate since the CSSR plateaus at a survival of 4.5 years and thereafter, patients died from causes other than 
MCC. The 5-year overall survival rate (OSR) was 19% for group A.
Fifty-seven patients (group B) had surgery alone without post-operative adjuvant radiotherapy. 5-year and 10-year CSSRs 
were both 63% (P=0.8, using the logrank test when comparing the two groups of patients). The 5-year OSR was 30% and the 
10-year OSR was 13% (P=0.6, group A versus group B). Morbidity from radiotherapy was minimal. Only one patient with 
an ankle lesion did not take the skin graft well and had drainage for one year before healing. One patient had lymphoedema 
of the arm (which required a pressure garment) after axillary dissection and radiotherapy of 50 Gy in 25 fractions over 35 
days. Radiotherapy after surgical excision is well tolerated. It is recommended if there are high risk factors for recurrence and 
radiotherapy should be started as soon as possible after referral.
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Materials & methods
From the computerised registry system in the two centres 
(Allan Blair Cancer Centre, Regina Saskatchewan, and London 
Regional Cancer Program, London Ontario), a search for MCC 
was made in order to undertake our retrospective chart review. 
Data were collected on the extent and location of the disease 
at presentation, duration of disease, co-existing morbidities, 
previous irradiation, size of primary/node, timing of treatment, 
extent of surgery/radiotherapy, resection margin, radiotherapy 
technique, chemotherapy regimens, recurrent events, survival 
and final disease status. Actuarial survival was calculated using 
the Kaplan-Meier method and comparisons were using the 
logrank test. The Cox proportional hazards model was used for 
a multivariate analysis of risk factors.
There are 665 cases reported in the literature. In order to 
give some answers to the current controversies in management 
with a large enough number of patients, statistical analyses were 
performed.
Results
From 1987 to 2005, a total of 79 patients with definite 
MCC were found (51 from Regina and 28 from 
Ontario). This series consisted of 40 males and 39 
females with a median age of 80 years (range 48-94). 
The median follow up was 21 months (range 0.5-150.4). 
All except three had a primary skin lesion. Six patients 
presented with nodal metastases and three patients 
with distant metastases. 14/79 patients were referred to 
the cancer centres at the time of recurrence: two with 
local re currence, eight with nodal recurrence, two with 
both local and nodal recurrence, and two with distant 
recurrence. The median time before diagnosis was 
4 months (range: 0.5-36).
Twenty-two patients (group A) received radiothe-
rapy at the time of presentation, 21 being post-operative 
adjuvant treatment and one being primary treatment 
without surgery. The 5-year cause-specific survival rate 
(CSSR) was 42%. The 5-year rates equals the 10-year 
rate since the CSSR plateaus at a survival of 4.5 years 
and thereafter, patients died from causes other than 
MCC. The 5-year overall survival rate (OSR) was 19% 
for group A.
Fifty-seven patients (group B) had surgery alone 
without post-operative adjuvant radiotherapy. 5-year and 
10-year CSSRs were both 63% (P=0.8, using the logrank 
test when comparing the two groups of patients). The 
5-year OSR was 30% and the 10-year OSR was 13% 
(P=0.6, group A versus group B).
Only two patients in our series received concurrent 
chemotherapy and radiotherapy. Both were of young age 
for MCC, 48 and 55 years. The first of these two patients 
had nodal disease at presentation and died of cancer at 
21 months. The second patient had a 0.7 cm primary only 
and was alive and well at last follow-up at 51 months.
Morbidity from radiotherapy was minimal. Only 
one patient with an ankle lesion did not take the skin 
graft well and had drainage for one year before healing. 
One patient had lymphoedema of the arm (requiring 
a pressure garment) after axillary dissection and radio-
therapy of 50 Gy in 25 fractions over 35 days.
Two patients had rapid progression of their tumo-
ur while waiting for commencement of treatment. Two 
patients had successful salvage of recurrence (one local 
and one nodal recurrence respectively) by radiotherapy 
alone without surgery. Two patients had nodal recurrence 
just outside previous radiotherapy field, emphasising the 
importance of careful planning for adequate coverage.
Discussion
D i a g n o s i s  o f  M C C
The clinical diagnosis is made with the typical clinical 
presentation: a rapidly growing, painless, firm, non -
tender, shiny, bluish-red, intracutaneous nodule of
0.5-5 cm in diameter, sometimes it can take the form of 
a plaque. The tumour is usually localised to sun-exposed 
areas of the head and neck, but does occur in extremities, 
trunk, genitalia and perianal regions with a random 
distribution. In our series, the median time before 
diagnosis was 4 months (range: 0.5-36). Delay in the 
treatment delivery would result in poorer results. Those 
patients with rapidly progressive tumour should never be 
delayed or put on a waiting list for treatment.
Fine needle aspiration enables an early and con-
fident diagnosis of this aggressive tumour and an early 
planning of surgery [8]. Diagnostic pitfalls include the 
following. (a) Co-existence of primary cutaneous MCC in 
association with squamous cell carcinoma and basal cell 
carcinoma. This has the implication that an ordinary squ-
amous or basal cell carcinoma should be sectioned tho-
roughly to avoid missing the aggressive MCC component. 
(b) The presence of desmoplasia may mask the diagnosis 
of MCC [9]. (c) Malignant lymphoma is an important dif-
ferential diagnoses for undifferentiated cutaneous round 
cell tumours. Polymerase chain reaction and sequencing, 
and immunohistochemistry are in strumen tal in their eva-
luation [10].
Pa t t e r n  o f  f a i l u r e  &  p r o g n o s t i c  f a c t o r s
A typical pattern of failure is a high incidence of distant 
metastases with an overall rate of 40%, i.e., 25% at 
presentation, and 15% after radiotherapy; as well as 
a 30-65% regional recurrence rate. Interestingly in some 
patients, the tumour was indolent and well controlled 
by therapy. However in some studies, even stage 
I patients have a high risk of disease progression, with 
53% developing regional lymphadenopathy or visceral 
meta stases. The median survival for all disease stages 
was 47 months [11].
Prognosis is very poor, particularly when systemic 
disease is present. Locoregional recurrences result in 
poor prognosis even after treatment. Nodal involvement 
at some time has been observed in 65% of reported cases 
(20% at presentation, subsequently 45%), and distant 
metastases in 34%. It appears to be distant metastases 
rather than nodal relapse that accounts for the poor pro-
gnosis of this disease [12, 13].
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Systemic disease was nearly uniformly preceded by 
the appearance of nodal metastases and was uniform-
ly fatal regardless of subsequent therapy. This suggests 
an orderly cascade pattern of spread for this tumour, in 
which elective regional lymph node dissection may be 
justified. The recommendations for treatment include 
a wide excision of the primary tumour and either elective 
or early therapeutic regional node dissection [14]. The 
recent literature shows much controversy because adju-
vant radiotherapy was reported to have no benefit after 
adequate surgery [15]. However, another school of tho-
ught is that post-operative radiotherapy is the standard 
of care [16, 17]. There is also the controversy of tumour 
size greater than 1 cm being put into the high risk group 
eligible for the Trans-Tasman Radiation Oncology Group 
(TROG) study. In fact to date, the only one prospective 
trial that has been completed on MCC, was carried out 
by the TROG [18]. There is also dispute as to whether 
statistical non-significance of adjuvant treatment may still 
be clinically important [19].
Males are reported to have a worse prognosis inde-
pendent of stage and extent of therapy [12]. Young age, 
defined as less than 70 years, was found to be a good pro-
gnostic factor in the Australian study where the above 
prospective TROG study was compared with historical 
controls which fulfilled the same eligibility criteria [20].
A literature review on 665 reported cases was the-
refore undertaken by us in order to give some answers 
to the current controversies in management. Univariate 
analysis showed age of less than or equal to 65 years 
(P=0.009), size of less than or equal to 1 cm (P=0.02), 
and female rather than male (P=0.002), to be good pro-
gnostic factors. Among the three groups of patients, i.e., 
with or without post-operative radiotherapy, and primary 
radiotherapy without surgery, we performed univariate 
analyses. The group without postoperative radiothe-
rapy fared the best, and the group with post-operative 
radiotherapy fared second-best for CSSR (P=0.019). For 
OS, there was borderline significance among the groups 
of patients (P=0.067). Again, the group without post-
operative radiotherapy fared the best and post-operative 
radiotherapy second-best.
Multivariate analysis for CSSR showed that the 
group without post-operative radiotherapy (P=0.03), 
female (P=0.004), and size less than or equal to 1 cm 
(P=0.01) were significantly good prognostic factors. 
Multivariate analysis for OSR showed that the lack of 
co-morbid conditions (P=0.002), female (P=0.002), age 
less than or equal to 65 years (P=0.004) and size less 
than or equal to 1 cm (P=0.01) were significantly good 
prognostic factors.
The data in the literature were consistent with our 
own series of 79 patients. This study showed that 5-year 
OSR without post-operative radiotherapy patients have 
a trend to fare better, 30% versus 19%, than those with 
post-operative radiotherapy. Possible reasons which 
might explain why the group without post-operative 
radio therapy fared the best include potential bias from 
earlier stage, fewer co-morbid conditions or other good 
prognostic factors.
Other prognostic factors have been used as basis for 
treatment recommendation. These include small cell size 
and high mitotic rate which were associated with a low 
survival rate [20]. When cell size was excluded, males and 
depth of invasion were associated with a worse survival, 
although these were not statistically significant [20]. Post-
operative radiation or chemotherapy may reduce the risk 
of recurrences. It should be given for patients with poor 
prognostic features. In the literature, bad prognostic fea-
tures include the following: lymph node metastasis, size 
greater than 1 cm (in the TROG study [18]), size grea-
ter than 2 cm [15], male rather than female [2], positive 
nodes, recurrent disease or gross residual disease after 
surgery [18]. TROG used the subgroup greater than 1 cm 
as one of the eligibility criteria for the chemoradiation 
study and other authors have questioned this [15]. Our 
present study showed that 1 cm may be a good dividing 
line for use in clinical studies of MCC.
Surgery is the mainstay of initial treatment for 
MCC and surgery alone is effective for small tumours 
and adequate resection margins. Complete regression 
with primary radiotherapy in inoperable elderly patients 
[21-23] has been reported. Gross disease of 3 cm size was 
effectively treated by radiotherapy alone although the 
follow-up was only 18 months at the time of reporting 
[22]. This was contrasted by other reports where primary 
radiotherapy achieved partial regression only [24, 25]
The importance of post-operative radiation the-
rapy in the treatment of MCC has been addressed by 
Meeuwissen et al [16], Shaw et al [26], Hasle [27], and 
Savage et al [11]. In the Meeuwissen et al [16] series the 
total number of patients was 80. All 38 patients treated 
with surgery alone relapsed, with a median time to recur-
rence of 5.5 months, compared with 10/34 relapses in 
patients treated with combined surgery and radiotherapy, 
with a median time to recurrence of 16.5 months.
Conclusions
Since the rate of progression of MCC is unpredictable, 
referred patients should be assessed and treated without 
delay. Careful radiation therapy planning to avoid any 
geographical miss is recommended. The management 
of MCC remains controversial, particularly in the 
adjuvant settings. Due to the rarity of this disease 
further investigations with prospective controlled trials 
may require international multicentre collaborations. 
We suggest that it is probable that a 1 cm tumour size 
might be a good dividing line for eligibility criterion. This 
should be investigated further.
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